Medicine | Oncology
Prostate cancer
Treatment
Metastatic hormone-sensitive prostate cancer


Home > Disciplines > Medicine > Oncology > Prostate cancer > Treatment > MHSPC



INTRODUCTION: HORMONE-SENSITIVE PCA

PROGNOSTIC FACTORS

FIRST-LINE HORMONAL TREATMENT (Androgen deprivation therapy, ADT)
PREVENTION OF FLARE-UP
CONCOMITANT PHARMACEUTICAL TREATMENT

COMBINATION THERAPIES
COMPLETE ANDROGEN BLOCKADE (CAB)
NON-STEROIDAL ANTI-ANDROGEN (NSAA) MONOTHERAPY
INTERMITTENT VERSUS CONTINUOUS ANDROGEN DEPRIVATION THERAPY (IAD)
Potential other benefits of intermittent androgen deprivation
Practical aspects for intermittent androgen deprivation
Testosterone-guided androgen deprivation therapy
IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRIVATION THERAPY

HORMONAL TREATMENT COMBINED WITH CHEMOTHERAPY

OTHER TREATMENT OPTIONS

GUIDELINES FOR THE FIRST-LINE TREATMENT OF METASTATIC PROSTATE CANCER

GUIDELINES FOR HORMONAL TREATMENT OF METASTATIC PROSTATE CANCER

CONTRAINDICATIONS FOR VARIOUS THERAPIES





INTRODUCTION: HORMONE-SENSITIVE PCA


.

Bernard B, Sweeney CJ.
Management of metastatic hormone-sensitive prostate cancer.
Curr Urol Rep. 2015 Mar;16(3):14. doi: 10.1007/s11934-015-0488-8. Epub 2015 Feb 13.
Source | Full text | Similar articles



.

Buonerba C, Di Lorenzo G.
The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer.
Front Pharmacol. 2017 Oct 31;8:788. doi: 10.3389/fphar.2017.00788. eCollection 2017.
Source | Full text | Similar articles



.

Damodaran S, Lang JM, Jarrard DF.
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 Feb 7:101097JU0000000000000117. doi: 10.1097/JU.0000000000000117. [Epub ahead of print]
Source | Abstract | Similar articles



.

Markowski MC, Carducci MA.
Early use of chemotherapy in metastatic prostate cancer.
Cancer Treat Rev. 2016 Oct 3. pii: S0305-7372(16)30097-4. doi: 10.1016/j.ctrv.2016.09.017. [Epub ahead of print]
Source | Full text | Similar articles



.

Xu L, Pachynski RK.
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7.
Source | Full text | Similar articles



OVERVIEWS, BOOKS, AND GUIDELINES



Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D.
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
Cancers (Basel). 2019 Sep 12;11(9). pii: E1355. doi: 10.3390/cancers11091355.
Source . Similar articles



.

Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N.
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.
Am Soc Clin Oncol Educ Book. 2018 May 23;(38):363-371. doi: 10.1200/EDBK_200967.
Source | Book | Similar articles



.

Kretschmer A, Todenhöfer T.
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Eur Urol Focus. 2018 Nov 24. pii: S2405-4569(18)30360-2. doi: 10.1016/j.euf.2018.11.008. [Epub ahead of print]
Source | Full text | Similar articles



.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
Prostate Cancer Prostatic Dis. 2017 Dec 20. doi: 10.1038/s41391-017-0014-9. [Epub ahead of print]
Source | Full text | Similar articles



.

Mottet N, De Santis M, Briers E, Bourke L, Gillessen S, Grummet JP, Lam TB, van der Poel HG, Rouvière O, van den Bergh RCN, Cornford P.
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839-4. doi: 10.1016/j.eururo.2017.09.029. [Epub ahead of print]
Source | Full text | Similar articles




Paller CJ, Eisenberger MA.
Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm.
J Clin Oncol. 2019 Sep 4:JCO1901863. doi: 10.1200/JCO.19.01863. [Epub ahead of print]
Source . Similar articles



.

Purshouse K, Protheroe AS.
Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience.
Ther Adv Urol. 2019 Jan 8;11:1756287218820804. doi: 10.1177/1756287218820804. eCollection 2019 Jan-Dec.
Source | Full text | Similar articles




Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG.
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Eur Urol. 2019 Oct 31. pii: S0302-2838(19)30693-1. doi: 10.1016/j.eururo.2019.09.004. [Epub ahead of print]
Source . Similar articles




Thangasamy IA, Kwan EM, Teh J, Sathianathen N, Alghazo O, Siva S, Azad A, Murphy DG.
Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists.
BJU Int. 2019 Oct 29. doi: 10.1111/bju.14936. [Epub ahead of print]
Source . Similar articles




VanderWeele DJ, Antonarakis ES, Carducci MA, Dreicer R, Fizazi K, Gillessen S, Higano CS, Morgans AK, Petrylak DP, Sweeney CJ, Hussain M.
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.
J Clin Oncol. 2019 Sep 10:JCO1901595. doi: 10.1200/JCO.19.01595. [Epub ahead of print]
Source . Similar articles



.

Yu EY, Gillessen S, Mottet N.
What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Eur Urol Focus. 2018 Oct 1. pii: S2405-4569(18)30287-6. doi: 10.1016/j.euf.2018.09.015. [Epub ahead of print]
Source | Full text | Similar articles



NEWLY DIAGNOSED mHSPC


.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.
Source | Full text | Similar articles



.

Saad F.
Importance of early treatment in metastatic prostate cancer: a question of life or death.
Lancet Oncol. 2019 May;20(5):609-611. doi: 10.1016/S1470-2045(19)30155-X. Epub 2019 Apr 12.
Source | Full text | Similar articles
Comment on: Fizazi K, et al, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.
Source / Full text



FIRST-LINE HORMONAL TREATMENT


.

Varenhorst E, Klaff R, Berglund A, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG) Trial No. 5.
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
Cancer Med. 2016 Jan 14. doi: 10.1002/cam4.594. [Epub ahead of print]
Source | Full text | Similar articles



STATIN USE



Jung J, Lee C, Lee C, Kwon T, You D, Jeong IG, Hong JH, Ahn H, Kim CS.
Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
Korean J Urol. 2015 Sep;56(9):630-6. doi: 10.4111/kju.2015.56.9.630. Epub 2015 Sep 2.
Source | Full text | Similar articles



COMBINATION THERAPIES




TESTOSTERONE-GUIDED ADT



Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF.
Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Prostate. 2016 Feb;76(2):235-42. doi: 10.1002/pros.23117. Epub 2015 Nov 2.
Source | Full text | Similar articles



HORMONAL TREATMENT COMBINED WITH CHEMOTHERAPY


.

Abdel-Rahman O.
Combined Chemohormonal Strategy in Hormone-Sensitive Prostate Cancer: A Pooled Analysis of Randomized Studies.
Clin Genitourin Cancer. 2015 Dec 17. pii: S1558-7673(15)00334-1. doi: 10.1016/j.clgc.2015.12.004. [Epub ahead of print]
Source | Full text | Similar articles



.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Cancer Treat Rev. 2016 Sep 10. pii: S0305-7372(16)30088-3. doi: 10.1016/j.ctrv.2016.09.008. [Epub ahead of print]
Source | Full text | Similar articles



.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators..
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5.
Source | Full text | Similar articles



.

Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group..
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Int J Clin Oncol. 2016 Sep 10. [Epub ahead of print]
Source | Full text | Similar articles



.

Kapoor A, Hotte SJ.
Chemotherapy research for metastatic prostate cancer.
Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S140-S143.
Source | Full text | Similar articles



.

Scott E.
Re: Sweeney CJ, Chen YH, et al, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747
Urol Oncol. 2017 Mar;35(3):123. doi: 10.1016/j.urolonc.2016.12.021. Epub 2017 Feb 1.
Source | Full text | Similar articles



.

Shenoy N, Kohli M.
Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.
Indian J Urol. 2016 Oct-Dec;32(4):257-261.
Source | Full text | Similar articles



.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5
Source | Full text | Similar articles



.

Taneja SS.
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
J Urol. 2016 Oct;196(4):1124-5. doi: 10.1016/j.juro.2016.07.067. Epub 2016 Jul 18.
Source | Full text | Similar articles



.

Taneja SS.
Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
J Urol. 2016 Jan;195(1):94. doi: 10.1016/j.juro.2015.10.055. Epub 2015 Oct 23.
Source | Full text | Similar articles



.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol. 2016 Apr;69(4):563-73. doi: 10.1016/j.eururo.2015.09.013.
Source | Full text | Similar articles



CHEMOTHERAPY: CONS


.

Miñana López B.
Chemotherapy should not yet be considered in patients with hormono-sensitive metastatic prostate cáncer.
Actas Urol Esp. 2017 Feb 14. pii: S0210-4806(16)30206-6. doi: 10.1016/j.acuro.2016.11.008. [Epub ahead of print] Spanish.
Source | Full text | Similar articles



OTHER TREATMENT OPTIONS




CYTOREDUCTIVE RADICAL PROSTATECTOMY


.

Jaber Y, Reichard CA, Chapin BF.
Emerging role of cytoreductive prostatectomy in patients with metastatic disease.
Transl Androl Urol. 2018 Sep;7(Suppl 4):S505-S513. doi: 10.21037/tau.2018.06.06.
Source | Full text | Similar articles



.

Mathieu R, Korn SM, Bensalah K, Kramer G, Shariat SF.
Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
World J Urol. 2016 Aug 8. [Epub ahead of print]
Source | Full text | Similar articles



LOCAL TREATMENT OF THE PRIMARY TUMOR SITE


.

Moschini M, Soria F, Briganti A, Shariat SF.
The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients.
Prostate Cancer Prostatic Dis. 2016 Oct 25. doi: 10.1038/pcan.2016.52. [Epub ahead of print]
Source | Full text | Similar articles



RADIOSURGERY


.

Napieralska A, Miszczyk L, Stapor-Fudzinska M.
CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
Neoplasma. 2016 Jan 17;63(2). doi: 10.4149/218_150807N435. [Epub ahead of print]
Source | Full text | Similar articles